Pinsky PF, et al. - Given that breast cancer (BrCA) incidence is reduced by raloxifene, however, if it also decreases mortality from BrCA remains unclear, and BrCA survival would have to be worse for raloxifene users vs non-users for raloxifene to decrease incidence but not mortality, and therefore, researchers evaluated BrCA features as well as survival among raloxifene regular users (≥ 180 days in past year) vs non-users among women with invasive BrCA diagnosed from 2007-2015 at age 65-89 with prior Medicare Part D (prescription drug) enrollment. The participants were identified from SEER-Medicare. They identified 116,317 raloxifene non-users and 1,223 regular users. The chance of having hormone receptor negative cancers was significantly more and that of having T2+, N1+ and metastatic disease was less in users. In non-users and regular users, a total of 10,869 and 101 breast cancer deaths were reported, respectively. Compared with non-users, raloxifene users had no worse breast cancer-specific survival, this indirectly proves that raloxifene decreases breast cancer mortality.